Sagimet announces results from Phase 1 PK trial of denifanstat, resmetirom

Sagimet Biosciences (SGMT) announced positive results in the Phase 1 pharmacokinetic trial of a combination of its oral once-daily fatty acid synthase inhibitor, denifanstat, and a thyroid hormone receptor beta agonist, resmetirom. The Phase 1 PK trial of denifanstat and resmetirom was an open-label, 2-cohort study that enrolled 40 healthy adult participants. The objectives were to evaluate multiple-dose and single-dose pharmacokinetics, identify any potential drug-drug interactions, and assess the safety and tolerability of the combination. The combination of denifanstat and resmetirom was generally well-tolerated over the duration of the study, with no safety signals. No Serious Adverse Events occurred, and there were no clinically significant laboratory results, and no treatment discontinuations.